RxDoctor Payments Data

Brianna Crummey, NP

Family · Eastman, GANPI 1316509771

Payments from drug & device makers

$2,453in general payments, 2019–2025

Across 123 payments — averaging $19.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$363
  • UCB, Inc.$327
  • Otsuka America Pharmaceutical, Inc.$256
  • AstraZeneca$214
  • Novo Nordisk$164
  • AbbVie$159
  • plus $970 from 24 others

What the payments were for

  • Food & beverage$2,453100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,453 in reported general payments places this provider in the 80th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$74,068
Medicare patients
175
Services billed
1,444

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide112$134,118
MounjaroTirzepatide90$127,723
FarxigaDapagliflozin Propanediol88$97,230
EliquisApixaban100$81,364
JardianceEmpagliflozin67$72,759
TrulicityDulaglutide32$40,254
LinzessLinaclotide37$36,146
MyrbetriqMirabegron62$34,186
JanuviaSitagliptin Phosphate37$26,825
Combivent RespimatIpratropium/Albuterol Sulfate22$17,621
XareltoRivaroxaban24$14,436
TradjentaLinagliptin17$13,677
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$13,109
EntrestoSacubitril/Valsartan13$12,688
Breo ElliptaFluticasone/Vilanterol29$11,896

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$124$167,977122 claims
Novo NordiskOzempic$164$134,118112 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$214$115,370125 claims
Boehringer IngelheimJardiance, Combivent Respimat, Tradjenta, Spiriva Respimat$37$110,010118 claims
AbbVieLinzess$159$36,14637 claims
GSKTrelegy Ellipta, Breo Ellipta$14$25,00646 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$48$8,80814 claims
BayerKerendia$363$8,12011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,258 family providers in Georgia.

Other family in Eastman

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →